Suppremol Gmbh

Societe Des Produits Nestle S.a.

Lifecodexx Ag

Thomas Pohl

Peter Sondermann

Fabrizio Arigoni

Dominik Ter Meer

Nicole Rieth

Wera Hofmann

Uwe Jacob

Michèle Delley

Anna Carle

Mark Alan Schell

Daniela Ehehalt

Christoph Von Kalle

Martina Mueller

Carolin Direnberger

Marie-Camille Zwahlen

Reno Winter

Raymond David Pridmore

Beat Mollet

Marcus Benz

Ehehalt Daniela

Michele Delley

The present invention relates to novel formulations of soluble Fc receptors and especially to formulations containing high concentrations of soluble FcγRIIB receptor. The invention further relates to the use of such formulations as pharmaceutical compounds for the treatment of autoimmune diseases, infections and other conditions where the immune system is involved.

Highly concentrated formulations of soluble Fc receptors

The present invention relates to novel formulations of soluble Fc receptors and especially to formulations containing high concentrations of soluble Fc&#x3b3;RIIB receptor. The invention further relates to the use of such formulations as pharmaceutical compounds for the treatment of autoimmune diseases, infections and other conditions where the immune system is involved.

The present invention relates in essence to an in vitro method for determining the stability, such as the shelf stability; stability over time; shelf life of a composition which comprises or essentially consists of soluble human Fc gamma receptor IIA, MB, IIIA and/or 1 MB, said method comprising the steps of contacting a surface comprising human Fc gamma receptor IIA, MB, IIIA and/or 1 MB with a set amount of aggregated human IgG; contacting said surface comprising human Fc gamma receptor IIA, MB, IIIA and/or 1 MB with a set amount of said composition of soluble human Fc gamma receptor IIA, MB, IIIA and/or 1 MB; determining the amount of aggregated human IgG which is bound to said surface comprising said human Fc gamma receptor IIA, MB, IIIA and/or 1 MB, and comparing the amount of aggregated human IgG which is bound to said surface as determined in step (c) with a reference value and (thereby) determining the stability [shelf stability; stability over time; shelf life] of said composition which comprises or essentially consists of soluble human Fc gamma receptor IIA, MB, IIIA and/or 1 MB. The present invention also relates to aggregated human IgG obtainable by a method as defined herein, as well as to the use of the mentioned aggregated human IgG in the methods of the invention.

In vitro method for determining the stability of compositions comprising soluble Fc gamma receptor(s)

Disclosed herein are recognition molecules that bind with a first binding domain to the Fc epsilon receptor (Fc&#x3b5;eR) and with a second binding domain to the Fc gamma receptor IIB (FcyRIIB), as well as uses for such recognition molecules.

Antibodies directed to Fc gamma receptor IIB and Fc epsilon receptor

The present invention relates to a nucleic acid sequence which encodes a protein of SEQ ID NO: 1; a vector comprising said nucleic acid sequence and a host cell comprising said nucleic acid sequence or said vector. The present invention also relates to a protein obtained or obtainable by expression of said nucleic acid sequence or said vector in a host cell. Furthermore, the present invention relates to a protein encoded by a nucleic acid sequence of SEQ ID NO: 6. Additionally comprised by the present invention are pharmaceutical compositions and a method of manufacturing the same.

Vector encoding an Fc gamma receptor IIB protein and composition of the encoded protein

The present invention provides an anti-FcyRIIB antibodies which, in comparison to prior art antibodies, markedly increase ITIM phosphorylation of FcyRIIB and can thus be used for the treatment or prophylaxis of autoimmune diseases.

Anti-Fc-gamma receptor IIB antibodies and uses thereof

Growing community of inventors

Neuried, Germany

Thomas Pohl